

Study Number: IMM20704

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

C Number:

IMM20704

Study Gender:

Male

PWG Approval Date

See web page for date of PWG Approval

M12: Cytotoxic T Cell Activity

Test Compound: Resveratrol

CAS Number: 501-36-0

Date Report Requested: 03/20/2020

Time Report Requested: 12:54:40

Lab: NTP

Study Number: IMM20704
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

M12: Cytotoxic T Cell Activity
Test Compound: Resveratrol
CAS Number: 501-36-0

Date Report Requested: 03/20/2020
Time Report Requested: 12:54:40
Lab: NTP

Males: Study 2

Treatment Groups (mg/kg/day)

	0	156	312	625	1250	2500	50 mg/kg CPS
CTL Activity (0.75:1) ^a	15.56 ± 1.58 (8)	24.20 ± 3.31 (8)	27.50 ± 3.92 (8)	23.16 ± 5.71 (8)	17.48 ± 2.26 (8)	25.47 ± 4.07 (7)	-0.41 ± 0.22 (7) **
CTL Activity (1.5:1)	30.23 ± 2.86 (8)	42.12 ± 4.38 (8)	46.25 ± 4.70 (8)	38.52 ± 7.25 (8)	33.21 ± 3.27 (8)	44.95 ± 5.56 (7)	0.31 ± 0.93 (7) **
CTL Activity (3:1)	49.76 ± 4.70 (8)	59.09 ± 4.54 (8)	63.62 ± 4.57 (8)	55.02 ± 7.53 (8)	50.42 ± 4.46 (8)	64.32 ± 6.11 (7)	-0.02 ± 0.37 (7) **
CTL Activity (6:1)	64.92 ± 4.37 (8)	74.57 ± 3.06 (8)	75.10 ± 3.98 (8)	66.79 ± 5.45 (8)	67.87 ± 4.69 (8)	78.37 ± 5.92 (7)	1.05 ± 0.82 (7) **
CTL Activity (12.5:1)	76.87 ± 2.44 (8)	86.09 ± 3.08 (8)	85.72 ± 3.67 (8)	82.03 ± 5.10 (8)	82.26 ± 3.44 (8)	89.11 ± 4.54 (7)	2.49 ± 1.38 (7) **
CTL Activity (25:1)	88.86 ± 2.14 (8)	93.80 ± 2.63 (8)	94.25 ± 3.25 (8)	91.54 ± 3.89 (8)	87.32 ± 3.64 (8)	95.55 ± 2.30 (7)	5.53 ± 2.62 (7) **

Study Number: IMM20704

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

M12: Cytotoxic T Cell Activity

Test Compound: Resveratrol

CAS Number: 501-36-0

Date Report Requested: 03/20/2020

Time Report Requested: 12:54:40

Lab: NTP

LEGEND

Data are displayed as mean \pm SEM (N) unless otherwise noted.

Data displayed as a mean of (effector cell:target cell ratio)

CTL - Cytotoxic T Lymphocytes

^aCTL Activity is expressed as % target cell killing calculated as (sample Cr51 release - spontaneous Cr51 release / total Cr51 release - spontaneous Cr51 release)

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

**** END OF REPORT ****